MASTERKEY-265: Phase 1b/3 trial of T-VEC and pembrolizumab for unresectable stage IIIB-IV melanoma

At the European Cancer Congress (ECC) 2015, Georgina Long, BSc, PhD, MBBS, FRACP, of The University of Sydney, Sydney, Australia, discusses the safety data from the phase 1b part of MASTERKEY-265 , a phase 1b/3 clinical trial that was designed to evaluate the treatment of talimogene laherparepvec (T-VEC), a herpes simplex virus-1, and pembrolizumab, an anti-PD-1 antibody, for the treatment of patients with unresectable stage IIIB-IV melanoma.

Year of Production:
Running Time:
Color/Sound:

2015
02:13
Color/Sound

Comments are closed.